Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
c-Ret inhibitors act on RET, a receptor tyrosine kinase that guides neuronal and kidney development. The ret gene, short for rearranged during transfection, was described in 1985 as a transforming gene activated by DNA rearrangement. In 1996 RET was shown to transduce signals from glial cell line-derived neurotrophic factor (GDNF). Activating point mutations and RET gene fusions are studied in thyroid and lung tumor models. Selpercatinib and RPI-1 are inhibitors with RET as their main target, while BT-13 is described as a small-molecule RET agonist. Multikinase inhibitors such as regorafenib also block RET together with vascular endothelial growth factor receptors (VEGFR) and Raf kinases.
BT44 is a selective RET activator that effectively penetrates the blood-brain barrier. It demonstrates potential in modulating RET signaling pathways, making it valuable for research focused on neurodegenerative disorders and diabetes mellitus. Its unique properties position BT44 as a significant tool for investigating therapeutic strategies in these complex diseases.
